Spots Global Cancer Trial Database for ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Official Title: A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Study ID: NCT03295396
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this phase II trial is to determine the efficacy and safety of ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent high-grade glioma. This study will test the research hypothesis that histone H3 K27M mutation sensitizes to oral administration of ONC201 in gliomas.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, San Francisco, San Francisco, California, United States
Stanford Cancer Center, Stanford, California, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
New York University School of Medicine, New York, New York, United States
Columbia University, New York, New York, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
